Shares of Biosyent stock opened at C$9.80 on Thursday. Biosyent has a 52 week low of C$7.30 and a 52 week high of C$11.00. The firm has a market capitalization of $139.88, a P/E ratio of 29.70 and a beta of 1.11.
Biosyent (CVE:RX) last issued its quarterly earnings data on Wednesday, March 21st. The company reported C$0.10 earnings per share for the quarter, meeting the Zacks’ consensus estimate of C$0.10. Biosyent had a return on equity of 25.90% and a net margin of 23.96%. The company had revenue of C$5.90 million during the quarter.
TRADEMARK VIOLATION NOTICE: This article was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3295778/biosyent-rx-earns-accumulate-rating-from-bloom-burton.html.
BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.